These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36347212)

  • 1. Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review.
    Winthrop K; Isaacs J; Calabrese L; Mittal D; Desai S; Barry J; Strengholt S; Galloway J
    Semin Arthritis Rheum; 2023 Feb; 58():152120. PubMed ID: 36347212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
    Winthrop KL; Park SH; Gul A; Cardiel MH; Gomez-Reino JJ; Tanaka Y; Kwok K; Lukic T; Mortensen E; Ponce de Leon D; Riese R; Valdez H
    Ann Rheum Dis; 2016 Jun; 75(6):1133-8. PubMed ID: 26318385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
    Winthrop KL; Nash P; Yamaoka K; Mysler E; Khan N; Camp HS; Song Y; Suboticki JL; Curtis JR
    Ann Rheum Dis; 2022 Feb; 81(2):206-213. PubMed ID: 34615638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature.
    Sánchez González CO; Nieto González JC
    Reumatol Clin (Engl Ed); 2022 Oct; 18(8):453-458. PubMed ID: 34893459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
    Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
    Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study.
    Takabayashi K; Ando F; Ikeda K; Nakajima H; Hanaoka H; Suzuki T
    Mod Rheumatol; 2023 Nov; 33(6):1078-1086. PubMed ID: 36308397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study.
    Uchida T; Iwamoto N; Fukui S; Morimoto S; Aramaki T; Shomura F; Aratake K; Eguchi K; Ueki Y; Kawakami A
    Rheumatology (Oxford); 2023 Oct; 62(10):3358-3365. PubMed ID: 36794922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination.
    Galloway J; Raine T; Rivett L; Roberts J; Dews SA; Choy EH
    Clin Exp Rheumatol; 2022 Jul; 40(7):1432-1441. PubMed ID: 34874825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.
    Harigai M
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i34-i42. PubMed ID: 30806708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
    Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Thirunavukkarasu K; DeMasi R; Geier J; Kwok K; Wang L; Riese R; Wollenhaupt J
    Ann Rheum Dis; 2017 Jul; 76(7):1253-1262. PubMed ID: 28143815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of JAK-1 inhibitors.
    Clarke B; Yates M; Adas M; Bechman K; Galloway J
    Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii24-ii30. PubMed ID: 33950230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
    Colombel JF
    Inflamm Bowel Dis; 2018 Sep; 24(10):2173-2182. PubMed ID: 29788127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis.
    Alves C; Penedones A; Mendes D; Marques FB
    J Clin Rheumatol; 2022 Mar; 28(2):e407-e414. PubMed ID: 33902098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis.
    Kourbeti IS; Ziakas PD; Mylonakis E
    Clin Infect Dis; 2014 Jun; 58(12):1649-57. PubMed ID: 24647016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
    Bing N; Zhou H; Chen X; Hirose T; Kochi Y; Tsuchida Y; Ishigaki K; Sumitomo S; Fujio K; Zhang B; Valdez H; Vincent MS; Martin D; Clark JD
    Arthritis Rheumatol; 2021 Jul; 73(7):1155-1166. PubMed ID: 33455090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
    Mori S; Ogata F; Tsunoda R
    Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors.
    Choi W; Ahn SM; Kim YG; Lee CK; Yoo B; Hong S
    Clin Rheumatol; 2022 Jun; 41(6):1659-1663. PubMed ID: 35157164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.